Clinical Chemistry Siemens Point of Care - Urinalysis
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 54: 866-873, 2008. First published March 13, 2008; 10.1373/clinchem.2007.100040
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow HTML Page - index.htslp
Right arrow All Versions of this Article:
clinchem.2007.100040v1
54/5/866    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Seferian, K. R.
Right arrow Articles by Katrukha, A. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Seferian, K. R.
Right arrow Articles by Katrukha, A. G.
Related Collections
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2008;54:866-873.)
© 2008 American Association for Clinical Chemistry, Inc.

Proteomics and Protein Markers

Immunodetection of Glycosylated NT-proBNP Circulating in Human Blood

Karina R. Seferian1,a, Natalia N. Tamm1, Alexander G. Semenov2, Anastasia A. Tolstaya3, Ekaterina V. Koshkina4, Mihail I. Krasnoselsky5, Alexander B. Postnikov1, Daria V. Serebryanaya1, Fred S. Apple6, MaryAnn M. Murakami6 and Alexey G. Katrukha1

1 HyTest Ltd., Turku, Finland; 2 Department of Biochemistry, Moscow State University, Moscow, Russia; 3 Moscow Research Institute of Medical Ecology, Moscow, Russia; 4 67 City Hospital, Moscow, Russia; 5 Moscow State Medico- Stomatological University, Moscow, Russia; 6 Hennepin County Medical Center, University of Minnesota School of Medicine, Department of Laboratory Medicine and Pathology, Minneapolis, MN.

aAddress correspondence to this author at: HyTest Ltd., Intelligate, 6th floor, Joukahaisenkatu 6, 20520 Turku, Finland. Fax +358 25120909; e-mail karina.seferian{at}hytest.fi.

Background: Brain natriuretic peptide (BNP) or NT-proBNP (N-terminal fragment of BNP precursor) measurements are recommended as aids in diagnosis and prognosis of patients with heart failure. Recently it has been shown that proBNP is O-glycosylated in human blood. The goal of this study was to map sites on the NT-proBNP molecule that should be recognized by antibodies used in optimal NT-proBNP assays.

Methods: We analyzed endogenous NT-proBNP by several immunochemical methods using a broad panel of monoclonal antibodies specific to different epitopes of the NT-proBNP molecule.

Results: Treatment of endogenous NT-proBNP by a mixture of glycosidases resulted in significant improvement of the interaction between deglycosylated NT-proBNP and monoclonal antibodies (MAbs) specific to the mid-fragment of the molecule. MAbs specific to the N- and C-terminal parts of NT-proBNP (epitopes 13–24 and 63–76) were able to recognize glycosylated and deglycosylated protein with similar efficiency.

Conclusions: The central part of endogenous NT-proBNP is glycosylated, making it almost "invisible" for the antibodies specific to the mid-fragment of the molecule. Thus sandwich assays using even one antibody (poly- or monoclonal) specific to the central part of the molecule could underestimate the real concentration of endogenous NT-proBNP. MAbs specific to the N- and C-terminal parts of NT-proBNP (epitopes 13–24 and 63–76) are the best candidates to be used in an assay for optimal NT-proBNP immunodetection.




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
J. Mair
Clinical Significance of Pro-B-Type Natriuretic Peptide Glycosylation and Processing
Clin. Chem., March 1, 2009; 55(3): 394 - 397.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
A. G. Semenov, A. B. Postnikov, N. N. Tamm, K. R. Seferian, N. S. Karpova, M. N. Bloshchitsyna, E. V. Koshkina, M. I. Krasnoselsky, D. V. Serebryanaya, and A. G. Katrukha
Processing of Pro-Brain Natriuretic Peptide Is Suppressed by O-Glycosylation in the Region Close to the Cleavage Site
Clin. Chem., March 1, 2009; 55(3): 489 - 498.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
L. Frankenstein, A. Remppis, M. Nelles, B. Schaelling, D. Schellberg, H. Katus, and C. Zugck
Relation of N-terminal pro-brain natriuretic peptide levels and their prognostic power in chronic stable heart failure to obesity status
Eur. Heart J., November 1, 2008; 29(21): 2634 - 2640.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
J. P. Goetze, U. Dahlstrom, J. F. Rehfeld, and U. Alehagen
Impact of Epitope Specificity and Precursor Maturation in Pro-B-Type Natriuretic Peptide Measurement
Clin. Chem., November 1, 2008; 54(11): 1780 - 1787.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Association for Clinical Chemistry.